
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
SOBIV | Stockholm | SEK | Real-time | |
SOBIs | BATS Europe | SEK | Delayed | |
0MTD | London | SEK | Real-time | |
1SOBI | Milan | EUR | Real-time |
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Aloxi, Jyseleca, Kepivance, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Anders Ullman | 69 | 2023 | Director |
Stefan Del Prato | - | - | Member of Scientific Advisory Board |
Jonathan Robert Sanders Arch | - | - | Member of Scientific Advisory Board |
Ralf Pettersson | - | - | Member of Scientific Advisory Board |
Hans Wigzell | 87 | 2001 | Chairman of Scientific Advisory Board |
Stephen O'Rahilly | - | - | Member of Scientific Advisory Board |
Helena Saxon | 55 | 2011 | Director |
David D. Meek | 62 | 2024 | Independent Chairman |
Staffan Schuberg | 56 | 2020 | Independent Director |
Susanna Ronnback | 38 | 2024 | Deputy Employee Representative Director |
Filippa Stenberg | 40 | 2021 | Director |
Zlatko Rihter | 55 | 2024 | Director |
Mats Lek | 42 | 2023 | Employee Representative Director |
Katy Mazibuko | 52 | 2019 | Employee Representative Director |
Christophe Bourdon | 55 | 2023 | Independent Director |
Asa Kjellstrom | 63 | 2023 | Deputy Employee Representative Director |
Iris Loew-Friedrich | - | 2025 | Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review